Burning Rock Biotech Ltd.

Burning Rock Biotech Limited American Depositary Receipt represents equity interests in a biotechnology company focused on precision oncology solutions. The asset provides exposure to Burning Rock Biotech Limited, which specializes in next-generation sequencing (NGS)-based diagnostics for cancer therapy selection and individualized treatment guidance. The company’s core offerings include a diverse range of genetic testing products such as OncoCompass IO and OncoScreen IO, designed to aid decision-making across multiple cancer types including lung, breast, colorectal, and prostate cancers. Burning Rock Biotech Limited operates primarily within the Chinese healthcare market, serving hospitals, clinicians, and research institutions seeking advanced molecular diagnostics. As an American Depositary Receipt (ADR), this asset allows international investors to access shares of a non-US company in a US dollar-denominated security, facilitating global capital flows and simplifying cross-border investment processes. Burning Rock Biotech Limited ADRs play a role in expanding access to biotechnology innovation and supporting the development of personalized medicine in oncology.